摘要
免疫应答的有效激活需要双信号的作用。共刺激信号中B7家族在肿瘤免疫治疗中应用广泛,PD-L1是新发现的B7家族成员,其配体为PD-1。PD-1/PD-L1通路有负调控免疫反应的作用,是近年来研究的热点。本文对PD-1和PD-L1在正常组织及肿瘤组织中的表达情况,及PD-1/PD-L1通路在白血病、淋巴瘤、多发性骨髓瘤、再生障碍性贫血等血液系统疾病中的研究现况作一综述,旨在为血液系统疾病的治疗提供新的思路。
Cross-priming is an important mechanism to activate immune response,which includes two classical signal pathways.Co-stimulatory signals are essential in the effective activation and B7-family is considered to be one of the most important factor in immunotherapy.PD-L1 is a new member of B7 family,whose ligand is PD-1.PD-1/PD-L1 can down-regulate the activation of immune response,which has become a focus of research.This article reviewed the expression of PD-1/PD-L1 in normal tissue and tumor,focusing on the status of PD-1/PD-L1 pathway study in leukemia,lymphoma,multiple myeloma,aplastic anemia and so on,in order to provide a new way for treatment of hematologic diseases.
出处
《中国实验血液学杂志》
CAS
CSCD
2011年第6期1523-1527,共5页
Journal of Experimental Hematology
